Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
相关临床试验
10
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2013
已完成
3
30.0%
招募中
4
40.0%
终止
3
30.0%
暂无批准数据
- Under CEO Reshma Kewalramani, Vertex launched Casgevy, the first FDA-approved CRISPR gene-editing drug, and Journavx, a new class of non-opioid painkillers. - Vertex posted $12 billion in profit in 2025 with a market capitalization exceeding $100 billion, expanding beyond cystic fibrosis into neurological, hematological, and renal diseases. - Bahija Jallal rescued Immunocore from near-collapse, raised $130 million, and secured FDA approval for Kimmtrak, the world's first therapy for inoperable or metastatic uveal melanoma. - GSK's US president Maya Martinez-Davis oversaw five new drug launches in 2025, while Teal Health's Kara Egan brought the first FDA-approved at-home cervical cancer screening kit to market.
- Genentech exercised the first validated target option under its neuroscience collaboration with Recursion, advancing a previously unexplored target identified via AI-powered whole-genome CRISPR screening of over 1 trillion iPSC-derived neuronal cells. - REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis, demonstrated a median 43% reduction in polyp burden at three months in the Phase 2 TUPELO trial, with additional data expected at CGA-IGC in November 2026. - The FDA cleared the IND for REC-7735, a mutant-selective PI3Kα H1047R inhibitor with >100-fold selectivity over wild-type, with the Phase 1/2 ZINNIA trial set to begin in the second half of 2026. - Recursion reduced its 2026 cash operating expense guidance to below $375 million and reported a cash runway extending into early 2028, supported by $557 million in cash and equivalents.
- Recursion Pharmaceuticals is a clinical-stage biotech using AI and machine learning to industrialize drug discovery across oncology and rare diseases. - The company reported 2025 revenue of $74.26 million with a -851.51% net margin, though it beat EPS estimates for three consecutive quarters. - Analyst consensus remains mixed with a $7.83 price target representing 166% upside potential from the current $2.945 share price. - The company maintains substantial cash reserves from financing activities but faces dilution risk and prolonged cash burn with unproven commercial viability.
- Germany's Digital Act and Health Data Use Act are creating a transparent, scalable market for digital health applications, with the BfArM fast-track process enabling rapid DiGA approvals while maintaining rigorous quality standards. - The Health Data Lab at BfArM now provides access to anonymized data from 74 million statutorily insured individuals, forming Europe's largest health data pool for research and product development. - AI-driven biotech is accelerating drug discovery, with companies like Aignostics launching pathology foundation models such as Atlas 2 to reveal cellular patterns in tumors for more precise cancer therapies. - Major pharmaceutical players including Bayer, Boehringer Ingelheim, Roche, and Sanofi are forging AI partnerships to broaden research programs, accelerate laboratory workflows, and improve success rates in oncology, immunology, and neurology.
- Verge Genomics has rebranded as Verge Labs and laid off 90% of its workforce after its AI-designed ALS drug VRG50635 failed in early-stage clinical trials. - The experimental drug, targeting the PIKfyve enzyme, showed increased levels of neurofilament light chain protein, indicating it wasn't having the desired therapeutic effect. - The company is pivoting from drug development to providing AI-driven data services for target identification, patient selection, and biomarker prediction. - CEO Alice Zhang emphasized that setbacks are expected with transformational technologies and that learnings will be fed back into the platform for iterative improvements.
- Paris-based Generare raised €20 million in Series A funding to expand its platform that decodes microbial genomes to discover previously inaccessible small molecules for drug discovery. - The company discovered more than 200 novel molecules in 2025 alone, outpacing all other players in the field combined who found only a few dozen new compounds. - Generare aims to scale its molecular library tenfold by 2027 to over 2,000 molecules, targeting the estimated 97% of genomic data buried in unexplored microbial genomes. - The funding will support expansion of the company's proprietary dataset and platform capabilities, positioning it to supply differentiated chemical starting points for next-generation AI drug discovery algorithms.
- Recursion Pharmaceuticals reported encouraging Phase 1b/2 TUPELO trial data for REC-4881, an AI-discovered drug candidate for familial adenomatous polyposis (FAP). - The trial demonstrated meaningful polyp burden reductions with a manageable safety profile, prompting J.P. Morgan to upgrade the company. - Recursion plans to meet with the FDA in 2026 to define a potential registration pathway for REC-4881. - ARK Investment Management increased its holdings by acquiring more than 2.8 million shares following the positive clinical results.
- Valinor raised $13 million in seed funding led by CRV to scale its multimodal machine learning platform for predicting patient response to therapies. - The company's AI models are trained on proprietary matched datasets of patient-derived multi-omic samples and treatment outcomes to distinguish responders from non-responders. - The platform aims to improve clinical trial success rates, reduce R&D costs, and accelerate delivery of life-saving medicines to patients. - Funding will expand Valinor's proprietary datasets and recruit additional machine learning talent to advance data-driven decision-making in drug development.
- Carrick Therapeutics announced positive Phase 2 results for samuraciclib combined with fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer patients previously treated with CDK4/6 inhibitors. - The combination achieved a 55% overall response rate and 14.5-month median progression-free survival in patients without TP53 mutations, compared to 29% and 6.8 months with fulvestrant alone. - Samuraciclib represents a first-in-class oral CDK7 inhibitor that could provide a new treatment option for the 70% of second-line patients who are TP53 wild-type. - The company plans to advance samuraciclib into Phase 3 trials in 2026 based on these encouraging efficacy and safety results.
- REC-4881, an investigational MEK1/2 inhibitor, demonstrated a 43% median reduction in polyp burden after 12 weeks of treatment in FAP patients, with 75% of evaluable patients showing reductions. - The therapeutic effect persisted 12 weeks after treatment cessation, with 82% of patients maintaining polyp burden reductions and a 53% median decrease from baseline at week 25. - The drug represents the first MEK1/2 inhibitor studied clinically for FAP, discovered through Recursion's AI-driven platform that identified MEK1/2 inhibition as a rescue mechanism for APC loss-of-function. - Recursion plans to engage the FDA in the first half of 2026 to define a potential registration pathway for this orphan disease affecting over 50,000 patients in the US and EU5.
